E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10040767 |
E.1.2 | Term | Sjogren's syndrome |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To characterize the dose-response relationship of LOU064 based on change from baseline in ESSDAI at Week 24 |
|
E.2.2 | Secondary objectives of the trial |
To evaluate:
- the efficacy of LOU064 compared to placebo with respect to change from baseline on patient- and physician-reported outcomes over time.
- the dose-response profile of LOU064 based on change in ESSPRI at Week 24.
- the efficacy of LOU064 compared to placebo with respect to change from baseline in ESSDAI over time.
- the safety and tolerability of LOU064.
To assess PK parameters of LOU064. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Signed informed consent must be obtained before any study assessment is performed.
2. Male or female patients aged 18 to 75 years at screening.
3. Classification of Sjögren's Syndrome according to the 2016 ACR/EULAR criteria at screening.
4. Screening ESSDAI (based on weighted score) ≥ 5 from 8 defined domains (biologic, hematologic, articular, cutaneous, glandular, lymphadenopathy, renal, constitutional). Patients with involvement of one or more of the remaining 4 domains are eligible but scores of these domains will not contribute to the assessment for eligibility, but will be part of the overall ESSDAI score for that subject.
5. Screening ESSPRI ≥ 5.
6. Seropositive for anti-Ro/SSA antibodies at or within 3 months prior to screening
7. Unstimulated whole salivary flow rate of > 0 mL/min at screening |
|
E.4 | Principal exclusion criteria |
1. Sjögren’s Syndrome overlap syndromes where another autoimmune disease constitutes the primary illness.
2. Rituximab or other B cell depleting drug within 12 months of Screening. For subjects who received such drug, their B cell count should be within normal range.
3. Prior treatment with any of the following within 6 months of baseline:
• CTLA4-Fc Ig (abatacept)
• Anti-TNF-α mAb
• Intravenous Ig
• Plasmapheresis
• i.v. or oral cyclophosphamide
• i.v. or oral cyclosporine A
4. Required regular use of medications known to cause, as a major side effect, dry mouth / eyes, and which have not been on a stable dose for at least 30 days prior to Screening, or any anticipated change in the treatment regimen during the course of the study.
5. Significant bleeding risk or coagulation disorders, including but not limited to:
• History or presence of thrombotic or thromboembolic event, or increased risk for thrombotic or thromboembolic event
• Requirement for anti-platelet or anticoagulant medication (for example, warfarin, or clopidogrel or Novel Oral Anti-Coagulant - NOAC) other than acetylsalicylic acid (up to 100 mg/d)
• History of gastrointestinal or intracerebral or otherwise severe prior bleeding events, including in association with use of Nonsteroidal Anti-Inflammatory Drug (NSAID)
6. Screening CBC laboratory values as follows:
• Hemoglobin levels below 10 g/dL
• Total leukocyte count less than 3,000/µL
• Platelets less than 100,000/µL
• Neutrophil count ≤ 1,500/ µL |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline in ESSDAI at Week 24 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Change from baseline in ESSPRI, FACIT-F, EQ-5D and PhGA over time.
- Change from baseline in ESSPRI at Week 24.
- Change from baseline in ESSDAI over time.
- PK parameters AUC, Cmax, Tmax and MRT and others as needed.
- Safety endpoints will include but not be limited to:
- Occurrence of treatment emergent adverse events (both serious and non-serious) during the study.
- Occurrence of treatment emergent abnormal vital signs, laboratory and ECG during the study. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 7 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 40 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Bulgaria |
China |
Denmark |
Germany |
Hungary |
Poland |
Spain |
Switzerland |
Taiwan |
United Kingdom |
United States |
Jordan |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Study completion is defined as the date when the last subject finishes their Study Completion visit and any repeat assessments associated with this visit have been documented and followed-up appropriately by the Investigator or, in the event of an early study termination decision, the date of that decision. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |